Skip to content

The French Multiple Sclerosis Registry

The French Multiple Sclerosis Registry

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02889965
Acronym
OFSEP
Enrollment
54000
Registered
2016-09-07
Start date
2011-01-31
Completion date
2019-12-31
Last updated
2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders

Keywords

Multiple sclerosis, Pharmacoepidemiology, Disease modifying drugs, Neuro-myelitis optica

Brief summary

OFSEP is an observational cohort of Multiple Sclerosis (MS) and related disorders set up in France. It aims to provide a major epidemiological tool on MS for the scientific community in France and abroad. This tool must help to answer a large number of questions concerning the causes and mechanisms of MS, the prognostic factors of disease progression, the effectiveness and safety of therapeutic drugs, the impact of the disease on patients and society, etc. In December 2015, it has already included more than 54.000 patients. To achieve this goal, OFSEP's objectives are * To maintain and develop the French cohort of patients suffering from MS or related diseases and syndromes. This means collecting standardized socio-demographic and clinical data as part of the routine medical follow-up of patients already in the cohort and recruitment of new patients. * To supplement the existing clinical data with standardized and quality biological samples and MRI scans. * To improve the previous data with medical/administrative data from the health insurance fund databases in particular, in order to get more information on comorbidity, treatment protocols and the medico-economic aspects of this disease. * To use OFSEP infrastructures to facilitate the implementation of specific studies requiring the collection of additional data or specific patient monitoring processes. * To ensure the availability of these data and samples to researchers, health care authorities and industrial players to enable analysis and thus provide answers to research questions or public health issues. This availability is only possible after scientific and regulatory evaluation of the request. * To provide regular descriptions of the patient population in the cohort to offer statistics, targets and up-to-date information on this disease and thus enable a better approach to the personal, professional and social impacts of the illness, the effects of basic treatments and the requirements related to the follow-up of this disease in France. * To conduct specific studies on the entire population of patients in the cohort (parent cohort) or on patient sub-groups with specific characteristics (nested cohorts). Four nested cohorts have been defined: patients with radiologically isolated syndromes, patients with clinically isolated syndromes, patients with primary progressive courses of the disease and patients with neuromyelitis optica (Devic's syndrome) spectrum disorders.

Interventions

None listed

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 100 Years
Healthy volunteers
No

Inclusion criteria

* RIS * CIS * MS according to McDonald 2010 criteria * NMOSD and others as per NOMADMUS criteria * No age limt * All clinical courses * Domiciliated in France * Signed OFSEP informed consent

Exclusion criteria

NONE \-

Design outcomes

Primary

MeasureTime frame
geographical distribution6 months up to 8 years
disease characteristics6 months up to 8 years
simple disease-modifying treatment description6 months up to 8 years
Number of cases of MS included6 months up to 8 years
number of patients6 months up to 8 years
demographic characteristics6 months up to 8 years

Countries

France

Contacts

Primary ContactSandra VUKUSIC
sandra.vukusic@chu-lyon.fr33 4 72 35 73 42
Backup ContactVéronique MILLOT
veronique.millot@chu-lyon.fr33 4 72 35 73 42

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026